sequella | 502487-67-4

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: sequella
• 英文别名: SQ109；N-adamantan-2-yl-N’-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine；N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine；N'-(2-adamantyl)-N-[(2E)-3,7-dimethylocta-2,6-dienyl]ethane-1,2-diamine
• CAS: 502487-67-4
• 化学式: C₂₂H₃₈N₂
• 分子量: 330.557
• InChiKey: JFIBVDBTCDTBRH-REZTVBANSA-N

物化性质

• 沸点：
  450.0±33.0 °C(Predicted)
• 密度：
  0.97±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮（少许）、氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

制备方法与用途

描述：SQ109 是一种抗结核药物，用于治疗耐多药结核病（MDR-TB）。

药物活性：SQ109 对幽门螺杆菌和白色念珠菌有活性，并可能具有广谱抗菌作用。它通过抑制 MmpL3 的活性来发挥作用，MmpL3 是一种将分枝酸整合到结核分枝杆菌细胞壁中所必需的转运蛋白。

用途：SQ109 是一种正在研发中的药物，旨在治疗包括耐药和广泛耐药结核菌株在内的多种结核病。

反应信息

• 作为反应物：
  描述：

  sequella 在 盐酸 作用下， 以 甲醇 为溶剂， 以0.75 g的产率得到N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine dihydrochloride
  参考文献：
  名称：

  Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates

  摘要：

  As part of an ongoing project to develop highly potent anti-tuberculosis therapeutics, six SQ109 derivatives were synthesized and screened in vitro for their anti-tuberculosis activity against the ATCC strain H37Rv and the extensively drug-resistant clinical strain XDR 173. Compound 16 with an extended alkene chain was the most active against both strains of Mycobacterium tuberculosis within a MIC range of 0.5-0.25 mu M. Compound 12 and SQ109 were potent within a MIC range of 1-0.5 mu M, whilst compound 18 displayed an activity within the MIC range of 0.5-2 mu M against both Mycobacterium tuberculosis strains. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.01.046
• 作为产物：
  描述：

  在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 sequella
  参考文献：
  名称：

  新型线性二胺二取代多环“笼”衍生物作为潜在的抗分枝杆菌候选

  摘要：

  作为一项正在进行的开发高效抗结核治疗药物的项目的一部分，合成了一系列新型多环“笼”四胺，并筛选了针对肺结核H 37 Rv菌株的体外抗结核活性。在这项研究中使用了三个双取代的多环部分，即五环癸烷，五环十一烷和三环癸烷。化合物5和7表现出相似的活性SQ109以1μ一个MIC米而化合物4，6和8在1

  DOI：

  10.1111/j.1747-0285.2011.01242.x

文献信息

• Benzothiazinone compounds and their use as anti-tuberculosis agents
  申请人：The University of Queensland

  公开号：EP2468746A1

  公开（公告）日：2012-06-27

  Novel benzothiazinone derivatives of formula (I) or a pharmaceutically acceptable salt or solvate thereof have been found to be effective against Mycobacterium tuberculosis strains and may thus be useful in the treatment of tuberculosis: wherein EWG (electron withdrawing group) = NO2, CN, CF3, F, Cl, Br, OCF3, OH, OR, OCHF2, COOR, wherein R is hydrogen, or a straight or branched C1-C4 alkyl group, X a bond, or a straight or branched C1-C4 alkylene group; Y = a bond, or a straight or branched C1-C4 alkylene group; wherein either one of X or Y is a bond and the other is a C1-C4- alkylene group, Z = N or C, n = 1 or 2; R1 = hydrogen, a straight or branched C1-C6 alkyl group, or a C3-C6 cycloalkyl group, which may be substituted with a group selected from F, Cl, Br, I or a C1-C4 alkoxy ; R2 = a phenyl group, a naphthyl group or a thienyl group, each of which may be unsubstituted or substituted with one or more substituent(s) which may be the same or different from each other, selected from the group consisting of F, Cl, Br, I, CN, NO2, or a straight or branched C1-C6 alkyl or phenyl group, which may be substituted with a group selected from F, Cl, Br, I, or C1-C4 alkoxy.

  化合物（I）的新型苯并噻唑酮衍生物或其药学上可接受的盐或溶剂已被发现对结核分枝杆菌菌株有效，并因此可能在结核病治疗中有用：其中EWG（电子提取基团）= NO2、CN、CF3、F、Cl、Br、O 、OH、OR、OCHF2、COOR，其中R为氢，或直链或支链C1-C4烷基；X为键，或直链或支链C1-C4亚烷基；Y = 键，或直链或支链C1-C4亚烷基；其中X或Y中的一个为键，另一个为C1-C4亚烷基，Z = N或C，n = 1或2；R1 = 氢，直链或支链C1-C6烷基，或C3-C6环烷基，可用F、Cl、Br、I或C1-C4烷氧基中选择的基团取代；R2 = 苯基，萘基或噻吩基，每个基团可以未取代或取代一个或多个取代基（s），其可相同或不同于来自F、Cl、Br、I、CN、 或直链或支链C1-C6烷基或苯基的基团，可用F、Cl、Br、I或C1-C4烷氧基中选择的基团取代。
• Methods of use and compositions for the diagnosis and treatment of infectious disease
  申请人：——

  公开号：US20030236225A1

  公开（公告）日：2003-12-25

  Methods and compositions for treating disease caused by microorganisms, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

  方法和组合物用于治疗由微生物引起的疾病，特别是结核病。具体而言，提供了用于治疗传染病的取代乙烯二胺的方法和组合物。在一种实施方式中，这些方法和组合物用于治疗分枝杆菌感染，包括但不限于结核病。
• COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES
  申请人：Locher Christopher Phillip

  公开号：US20140045791A1

  公开（公告）日：2014-02-13

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

  本发明涉及式(I)化合物或其药学上可接受的盐，其中X和R的定义如本文所述。式(I)化合物可用作抑制DNA旋转酶和/或拓扑异构酶IV的抑制剂，用于治疗细菌感染。式(I)化合物具有广泛的抗菌活性和优越的毒理学特性，或者是具有该活性的前药。
• ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS
  申请人：PROTOPOPOVA Marina Nikolaevna

  公开号：US20090192173A1

  公开（公告）日：2009-07-30

  Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.

  本发明提供了用于治疗由传染性病原体引起的疾病，特别是结核病的方法和组合物。具体而言，提供了用于治疗传染病的取代乙二胺的方法和组合物。在一个实施例中，这些方法和组合物用于治疗分枝杆菌感染，包括但不限于结核病。在某些实施例中，本发明包括包含新型取代乙二胺化合物的组合物，进一步包括抗结核药物如利福平、异烟肼、吡嗪酰胺和乙胺丁醇。
• COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES
  申请人：Reddy Venkata

  公开号：US20090281054A1

  公开（公告）日：2009-11-12

  Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis are provided. In particular, methods and compositions comprising substituted derivatives of capuramycin analogs for the treatment of infectious diseases are provided. Also provided are capuramycin analogue formulations comprising PEGylated compounds, including a PEGylated vitamin E derivative, liposomes and nanoparticle carriers. The invention provides methods and compositions comprising a capuramycin analogue and capuramycin analogues in combination with one or more other active agents.

  提供了治疗由感染性病原体引起的疾病的方法和组合物，特别是结核病。具体提供了包含替代的卡普拉霉素类似物衍生物的方法和组合物，用于治疗传染病。还提供了包括PEG化化合物（包括PEG化维生素E衍生物）、脂质体和纳米粒载体的卡普拉霉素类似物制剂。本发明提供了包括卡普拉霉素类似物和卡普拉霉素类似物与一个或多个其他活性剂的组合物和方法。